Introducing ADI’s new CEO: Dr. Faith Mwangi-Powell
ADI announces our new CEO, joining on 1 October 2026
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Living Between Scans: Uncertainty, Hope and Life After a Dementia Diagnosis
In this guest article, ADI Board Member and dementia advocate, Bill Yeates, shares his post diagnosis journey, discussing the hopes and challenges of life between scans.
Italian national dementia plan to receive funding for first time
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI’s 34th international and 1st virtual conference opens
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
People with dementia must be priority for COVID-19 vaccine access
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Open to all: British Land and Canada Water
Emma Cariaga and Ginny Warr of British Land explore what inclusive design means for older people and for business growth. They look at Canada Water, where British Land is creating London’s first new town centre in over 100 years, and at activities across the company’s wider portfolio.
‘Dementia, lessons learned from Qatar’ launched at WISH 2020 Qatar Summit
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
New Alzheimer’s disease data platform launched
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Souvenaid results offer hope for those with early Alzheimer’s disease, including Mild Cognitive Impairment
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
Evidence considered at FDA Advisory Committee for potential first new Alzheimer’s disease treatment in decades
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.